表紙
市場調査レポート

医療機器有力企業シリーズ:無針注射器の主要な開発企業・メーカー・販売企業 (2016年)

Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016

発行 Visiongain Ltd 商品コード 253510
出版日 ページ情報 英文 174 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.57円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医療機器有力企業シリーズ:無針注射器の主要な開発企業・メーカー・販売企業 (2016年) Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016
出版日: 2016年06月13日 ページ情報: 英文 174 Pages
概要

当レポートでは、世界の無針注射器市場の主要企業28社 (開発企業・メーカー・販売企業) の動向について調査分析し、各社の業績や、上市済み/治験中の主要製品の一覧、事業展開・資本取引の動きなどを調査すると共に、世界市場の動向見通し (今後11年間分) や、主な市場促進・抑制要因、製品カテゴリー別・地域別の詳細動向、業界全体の競争力や市場競争の情勢、専門家の見解、今後の市場成長の方向性といった情報を取りまとめてお届けいたします。

第1章 分析概要

第2章 無針 (ニードルフリー) 注射の概略

  • 無針ドラッグデリバリーとは?
  • 無針注射の原理
  • 無針ドラッグデリバリーの用途
  • 無針デリバリーデバイスの規制
  • 無針システムのメリット・デメリット

第3章 世界の無針注射器市場

  • 世界の無針注射器市場
  • 世界の無針注射器市場:収益予測 (今後11年間分)
  • 市場成長の主な促進要因
  • 市場成長の主な抑制要因
  • 世界のジェット式注射器市場
  • 世界の競合技術の市場
    • 業界動向 (今後11年間分)
      • 経皮パッチ:魅力的かつ安価なオプション
      • マイクロニードル (顕微針):集団予防接種向けの巨大な潜在的市場
      • 計量式吸入器:製品改良に伴う普及促進
  • 無針注射技術:市場動向 (今後11年間分)
  • 無針注射技術:市場促進・抑制要因

第4章 北米の主な無針注射器メーカー

  • Antares Pharma
  • Mylan Inc.
  • Bioject Medical Technologies
  • Activa Brand Products, Inc.
  • D'Antonio Consultants International Inc. (DCI)
  • National Medical Products, Inc.
  • Medical International Technologies
  • Penjet Corporation
  • PharmaJet
  • Valeritas
  • 3M (MMM)
  • Zogenix
  • BD - Becton, Dickinson and Company
  • Portal Instruments

第5章 欧州の主な無針注射器メーカー

  • Akra Dermojet
  • Crossject Medical Technology
  • Glide Pharma
  • Merck KGaA
  • Spirit Healthcare
  • AstraZeneca

第6章 新興国市場の主な無針注射器メーカー

  • Injex Pharma AG
  • Romsons Scientific & Surgical Pvt. Ltd.
  • Binny's Health Care Ltd

第7章 他の国々 (RoW) の主な無針注射器メーカー

  • Mika Medical Co.
  • JMS Singapore Pte Ltd
  • B. Braun Singapore Pte Ltd.
  • NanoPass Technologies
  • Vaxxas

第8章 世界の無針注射器市場の定性分析

  • SWOT分析
  • STEP分析 (社会的・技術的・経済的・政治的要因)

第9章 専門家の見解

  • Mr David Hoey (CEO, Vaxxas)

第10章 結論

  • 世界の無針注射器市場の将来展望
  • Antares Pharmaが世界市場を独占
  • 強力なパイプライン製品の存在が、今後の技術開発競争を促進
  • 無針注射器技術の将来性
  • バイオシミラーが今後の市場成長を促進
  • まとめ

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0122

Title:
MEDICAL DEVICE LEADER SERIES: TOP NEEDLE-FREE INJECTION DEVICE DEVELOPERS, MANUFACTURERS AND MARKETERS IN 2016
Market Analysis Including Antares Pharma, PharmaJet, Mylan and Other Firms in North America, Europe, Israel and Asia Pacific, Covering Jet Injectors, Transdermal Patches, Microneedles, Pen Injectors and Other Drug Delivery Systems.

Needle-Free Drug Injecting Technologies - Discover Leading Companies' Products, Developments, Results and Potentials

What does the future hold for producers of needle-free injection (NFI) products? Visiongain's updated, expanded report shows you data to 2026 for that industry and market. There you find analysis, trends, opportunities, prospects and revenue forecasting. Don't miss out.

Our new study analyses 28 leading developers and producers of those medical devices. NFI drug delivery holds great potential from 2016 for the therapeutic and commercial advancement of biologics and vaccines. Discover what that progress means and how you can benefit your work and influence.

So read on, please, to scan that industry's leading participants and see what its future market could be worth.

Results and forecasting to help you stay ahead in knowledge on those medical injectors

With our study you examine the industry for needleless injection and needle-free syringes - insulin injectors and other systems. Explore that industry's progress. See the potential for novel and improved subcutaneous, intradermal, intramuscular and intravenous drug delivery.

That market advances fast. In our report you assess product ranges, historical data, R&D, sales prediction and financial results. There you gain quantitative and qualitative analyses. In our 173 page report you find 74 tables, 9 charts and an interview with a prominent company.

NFI technology - discover how to benefit your work, also finding where the money lies

In our analysis you see how developers overcome problems with parenteral drug application, especially benefiting the use of biological drugs. You also discover potential revenues.

The following sections explain how our new investigation can benefit your work.

Companies based in North America - what are their outlooks?

First our study gives you financial data and discussions for prominent North American NFI developers and manufacturers:

  • Antares Pharma
  • Bioject Medical Technologies
  • Activa Brand Products
  • D'Antonio Consultants International
  • National Medical Products
  • Medical International Technologies
  • Penjet Corporation
  • PharmaJet
  • Valeritas
  • 3M
  • Zogenix
  • Mylan
  • Becton, Dickinson and Company
  • Portal Instruments.

Discover what the present and future hold for leading companies. Also see revenue predictions to 2026 for the overall world industry for needle-free injection devices.

Also hear about developments and prospects of firms in other countries.

Europe - outlooks for leading developers and producers of medical injection technology

Next our report analyses European-based specialists in that drug delivery:

  • Akra Dermojet
  • Crossject Medical Technology
  • Glide Pharma
  • Merck KGaA
  • Spirit Healthcare
  • AstraZeneca.

Many commercial opportunities exist, with expanding revenues possible from 2016 to 2026. Explore companies well placed to succeed. That way you see how organisations gain advantages, develop technologies and increase revenues.

Companies in other regions - developed and developing countries' technologies

How do companies in India, China, South Korea, Singapore, Israel and Australia contribute? Our report shows activities, results and outlooks of these organisations:

  • Injex Pharma AG
  • Romsons Scientific & Surgical
  • Binny's Health Care
  • Mika Medical Co.
  • JMS Singapore
  • B. Braun Singapore
  • NanoPass Technology
  • Vaxxas.

With our survey you discover progress, potentials and R&D across the world, assessing what is possible from 2016. Stay ahead in knowledge to help your work.

Events and forces affecting developers, producers and sellers of NFI technologies

Our study explains issues affecting that industry and market from 2016, including these influences:

  • Jet injector devices, transdermal patches, microneedles, pen injectors and other systems
  • Applications - pain management, vaccine delivery, treating diabetes, paediatric medicine and other uses, including self-administration and home-based therapy
  • Regulations affecting that medical equipment industry - challenges and opportunities
  • Solid formulations and other issues, innovations and developments
  • Deals, collaborations and other changes affecting those technology providers.

There you explore political, economic, social and technological questions, investigating outlooks for business. Examine what stimulates and restrains that industry and market.

Our study forecasts that overall worldwide sales of needle-free injection devices will reach $1.98 billion in 2020, with strong sales growth to 2026. With that analysis you explore how those companies, progress, compete and succeed. Avoid missing out on data.

You also read opinions from a company we interviewed. See what that industry's present and future hold, assessing opportunities for companies to contribute, expand and benefit.

Six main ways Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016 helps your work

Our report gives the following knowledge to benefit your research, analyses, plans, decisions and presentations:

  • Analysis of 28 companies' needle-free injection products and technologies
  • Investigation of firms' research and development
  • Coverage of organisations' strengths, weaknesses, activities, outlooks and prospects
  • Revenue forecasting and discussions for that industry from 2016 to 2026
  • Comments from the CEO of a leading company, revealing insight in our interview
  • Assessment - SWOT and STEP analyses - of the needle-free injection devices market, appraising that industry's present and future.

That investigation, by visiongain's in-house team in the UK, has the purpose of helping everyone interested in the future of needle-free injections and related drugs, instruments, containers and accessories. Discover analysis leading organisations depend on.

Analysis found nowhere else - explore the future of that medical device technology

With our research and analysis you are less likely to fall behind in knowledge or miss opportunity. There see how you could save time and effort. That way you could benefit your plans, decisions and presentations, helping you gain advantages and recognition.

Trying our study now lets you discover the latest progress and opportunities

Our new research is for everyone analysing drug delivery and pharmaceutical R&D. For leading companies and technologies you explore trends, progress and opportunities. So avoid missing out - please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Top Needle-Free Injection Device Manufacturers
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers Research and Analysis
  • 1.4. Main Questions Answered by This Analytical Study
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Needle-Free Injection

  • 2.1. What is Needle-Free Drug Delivery?
    • 2.1.1. History of Needle-Free Injections: From Military to Clinic
    • 2.1.2. Modern Needle-Free Devices: Concept of High Pressure Fluid Jet
  • 2.2. What is the Rationale for Needle-Free Injections?
  • 2.3. Applications of Needle-Free Drug Delivery
    • 2.3.1. Pain Management: Using NFI Devices to Administer Lidocaine
    • 2.3.2. Vaccine Delivery: Improving Immune Response
    • 2.3.3. Insulin Delivery: Jet Injection Enhances Drug Distribution
    • 2.3.4. Paediatrics: Alleviating Childhood Anxiety and Phobia
  • 2.4. Regulation of Needle-Free Delivery Devices
    • 2.4.1. The US Regulation System: Prolonged Approval Process
    • 2.4.2. The European Regulation System: Manufacturers Seeking EU Approval First?
  • 2.5. Advantages and Disadvantages of Needle-Free Systems

3. The Global Needle-Free Injection Devices Market, 2016-2026

  • 3.1. The Global Needle-Free Injection Device Market, 2016
  • 3.2. The Global Needle-Free Injection Device Market: Revenue Forecast, 2016-2026
  • 3.3. What Will Drive The Global Needle-Free Injection Device Market Between 2016 and 2026?
  • 3.4. What Factors are Likely to Restrain the Global Needle-Free Injection Device Market Between 2016 and 2026?
  • 3.5. The Global Jet Injector Device Market, 2016
    • 3.5.1. The Global Jet Injector Device Market: Industry Trends, 2016-2026
  • 3.6. The Global Competing Technologies Market, 2016
    • 3.6.1. The Global Competing Technologies Market: Industry Trends, 2016-2026
      • 3.6.1.1. Transdermal Patches: Attractive and Cheap Option
      • 3.6.1.2. Microneedle Technology: Huge Potential for Mass Vaccinations
      • 3.6.1.3. Metered Dose Inhalers: Change in Device Propellant to Drive Adoption
  • 3.7. Needle-Free Delivery Technology: Market Trends, 2016-2026
  • 3.8. Needle-Free Delivery Technology: Drivers and Restraints, 2016-2026

4. Leading North American Needle-Free Injection Device Manufacturers, 2016

  • 4.1. Antares Pharma
    • 4.1.1. Antares Pharma: Financial Overview
    • 4.1.2. Needle-Free Products
      • 4.1.2.1. ZOMAJET™: Delivering Liquid Insulin or Human Growth Hormone
      • 4.1.2.2. Vibex™: Hidden Needle to Alleviate Patient Fear
      • 4.1.2.3. OTREXUP™: Combining Vibex MTX and Methotrexate
      • 4.1.2.4. Vibex™ MTX: Targeting Growing Population of RA Sufferers
      • 4.1.2.5. T-JET™
    • 4.1.3. Needle-Free Injection Device Pipeline
      • 4.1.3.1. Vibex™ QS (QuickShot): Modified Vibex to Offer Improved Function
      • 4.1.3.2. Pen Injector: Devices Being Used Clinical Testing
      • 4.1.3.3. VIBEX® QS T
      • 4.1.3.4. VIBEX® QS M
  • 4.2. Mylan Inc.
    • 4.2.1. Mylan: Financial Overview
    • 4.2.2. Needle-Free Products
      • 4.2.2.1. EpiPen® Auto-Injector
      • 4.2.2.2. EpiPen Jr® Auto-Injector
  • 4.3. Bioject Medical Technologies
    • 4.3.1. Bioject Medical Technologies: Financial Overview
    • 4.3.2. Needle-Free Products
      • 4.3.2.1. Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
      • 4.3.2.2. Vitajet™: Low-Cost Insulin Delivery System
      • 4.3.2.3. Bioject® ZetaJet™: Auto-Disable Feature Improves User Safety
      • 4.3.2.4. Bioject® Drug Reconstitution System
      • 4.3.2.5. Bioject® Needle-Free Vial Adapter
    • 4.3.3. Needle-Free Injection Device Pipeline
      • 4.3.3.1. Intradermal Pen Injector: Targeted Drug Delivery
      • 4.3.3.2. Iject®: Providing Tailored Depth of Penetration
      • 4.3.3.3. Iject® R: The Reusable Version
      • 4.3.3.4. Jupiter Jet: Multi Dosing With Single Loaded Syringe
      • 4.3.3.5. Mega Jet: The New Design
    • 4.3.4. Collaborations
      • 4.3.4.1. MPI Research: Seeking Drug/Device Combinations
      • 4.3.4.2. World Health Organisation (WHO): The Push to Eradicate Infectious Disease in Developing Countries
  • 4.4. Activa Brand Products, Inc.
    • 4.4.1. Technology: The Activa Family for Diabetics
    • 4.4.2. Needle-Free Products
      • 4.4.2.1. Product Advantages
  • 4.5. D'Antonio Consultants International Inc. (DCI)
    • 4.5.1. Needle-Free Products
      • 4.5.1.1. LectraJet®: Lightweight Device Reduces User Fatigue
    • 4.5.2. Needle-Free Injection Device Pipeline
      • 4.5.2.1. Low Workload Jet Injector: Single-Shot Manuel System
      • 4.5.2.2. Multi-Channel Jet Injector: For Simultaneous Vaccine Delivery
  • 4.6. National Medical Products, Inc.
    • 4.6.1. Needle-Free Products
      • 4.6.1.1. J-Tip®: Offering Needle-Free Administration of Anaesthesia
  • 4.7. Medical International Technologies
    • 4.7.1. Needle-Free Products
      • 4.7.1.1. MED-JET®: Extremely Thin Orifice Offers Improved Drug Absorption
    • 4.7.2. Increased Awareness Through Globalisation
  • 4.8. Penjet Corporation
    • 4.8.1. Needle-Free Products
      • 4.8.1.1. Penjet®: Nitrogen-Powered Device Allows Efficient Storage
    • 4.8.2. Applications
      • 4.8.2.1. Multi-Component Drugs
      • 4.8.2.2. Lyophilised Drug Delivery
      • 4.8.2.3. Small Pox Vaccination
  • 4.9. PharmaJet
    • 4.9.1. Needle-Free Products
      • 4.9.1.1. STRATIS®: Drug Delivery in Less Than a Second
    • 4.9.2. Applications
    • 4.9.3. Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
  • 4.10. Valeritas
    • 4.10.1. Needle-Free Products
      • 4.10.1.1. Mini-Ject™: Potential Delivery of Lyophilised Drugs May Open Huge Opportunities for Valeritas
      • 4.10.1.2. V-Go®: Click and Go Technology to Simplify Insulin Drug Delivery
      • 4.10.1.3. Micro-Trans™:
      • 4.10.1.4. h-Patch™: Controlled Delivery Patch
  • 4.11. 3M (MMM)
    • 4.11.1. Needle-Free Products
      • 4.11.1.1. 3M: Metered Dose Inhaler
      • 4.11.1.2. 3M: Transdermal Patch
      • 4.11.1.3. 3M: Microneedle
  • 4.12. Zogenix
    • 4.12.1. Needle-Free Products
    • 4.12.2. Needle-Free Injection Pipeline
  • 4.13. BD - Becton, Dickinson and Company
    • 4.13.1. Needle-Free Products
      • 4.13.1.1. BD SmartSite
      • 4.13.1.2. Soluvia
      • 4.13.1.3. BD Ultra-Fine Nano Pen Needle
      • 4.13.1.4. AutoShield Duo Pen Needle (BD)
      • 4.13.1.5. BD Accuspray SCF Nasal Spray System
  • 4.14. Portal Instruments
    • 4.14.1. Needle-Free Products
      • 4.14.1.1. Portal's Needle-Free Jet Injector
      • 4.14.1.2. Partnering

5. Leading European Needle-Free Injection Device Manufacturers, 2016

  • 5.1. Akra Dermojet
    • 5.1.1. Needle-Free Products
      • 5.1.1.1. Dermojet® “HR”: User-Friendly Design Allows Use in High Intensive Applications
      • 5.1.1.2. DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
      • 5.1.1.3. Automatic DERMOJET®
  • 5.2. Crossject Medical Technology
    • 5.2.1. Technology: Highly Customisable Device Allows Tailoring to Specific Drugs
    • 5.2.2. Needle-Free Products
      • 5.2.2.1. Zeneo®: Gas Propellant Generated Upon Injection
  • 5.3. Glide Pharma
    • 5.3.1. Needle-Free Products
      • 5.3.1.1. Glide SDI®
      • 5.3.1.2. Applications
    • 5.3.2. Advantages
      • 5.3.2.1. Injecting Solid Formulations
      • 5.3.2.2. Pharmaceutical Companies
    • 5.3.3. Collaboration With Pfenex Inc. to Aid Delivery of Solid Dose Vaccine
  • 5.4. Merck KGaA
    • 5.4.1. Needle-Free Products
      • 5.4.1.1. Cool.click® and Cool.click2®
      • 5.4.1.2. Click.easy®
      • 5.4.1.3. SeroJet™
  • 5.5. Spirit Healthcare
    • 5.5.1. Spirit Healthcare Needle-Free Products
      • 5.5.1.1. InsuJet™
  • 5.6. AstraZeneca
    • 5.6.1. AstraZeneca's Needle-Free Product

6. Leading Emerging-Market Needle-Free Device Manufacturers, 2016

  • 6.1. Injex Pharma AG
    • 6.1.1. Needle-Free Products
      • 6.1.1.1. INJEX30®: First Multiple Application Needle-Free Device?
  • 6.2. Romsons Scientific & Surgical Pvt. Ltd.
    • 6.2.1. Needle-Free Products
      • 6.2.1.1. Safesite™
      • 6.2.1.2. Exteena™ Uno
      • 6.2.1.3. Exteena™ Duo
      • 6.2.1.4. Exteena™ Trio
  • 6.3. Binny's Health Care Ltd
    • 6.3.1. Needle-Free Products
      • 6.3.1.1. Binny's Needle-Free IV Injection

7. Leading Needle-Free Injection Companies in the Rest of the World, 2016

  • 7.1. Mika Medical Co.
    • 7.1.1. Needle-Free Products
      • 7.1.1.1. Comfort-in™
  • 7.2. JMS Singapore Pte Ltd
    • 7.2.1. Needle-Free Products
      • 7.2.1.1. Planecta™
  • 7.3. B. Braun Singapore Pte Ltd.
    • 7.3.1. Needle-Free Products
      • 7.3.1.1. CARESITE® Luer Access Device (LAD)
      • 7.3.1.2. SAFELINE® Split Septum Needleless Connector
      • 7.3.1.3. ULTRASITE® Luer Access Device
  • 7.4. NanoPass Technologies
    • 7.4.1. Nanopass Drug Delivery Products
      • 7.4.1.1. Micronjet Needle
      • 7.4.1.2. Anti-Aging Microdermabrasion
  • 7.5. Vaxxas
    • 7.5.1. Needle-Free Products
      • 7.5.1.1. The Nanopatch™

8. Qualitative Analysis of the Global Needle-Free Injection Device Market, 2016-2026

  • 8.1. SWOT Analysis of the Global Needle-Free Injection Device Market, 2016-2026
    • 8.1.1. Strengths
      • 8.1.1.1. A Less Painful Alternative to Needle-Based Injections
      • 8.1.1.2. No Specialist Training Required for Delivery
      • 8.1.1.3. Strong Growth in the Biologic Drug Market
      • 8.1.1.4. Increasing Development in Transdermal Delivery
      • 8.1.1.5. Reduced Transport Costs and Eliminating the Cold Chain Problem
    • 8.1.2. Weaknesses
      • 8.1.2.1. Expensive Technology
    • 8.1.3. Healthcare Practitioners Are Not Familiar with Novel Delivery Systems
      • 8.1.3.1. Inefficient Manufacturing Process
    • 8.1.4. Greater Regulatory Scrutiny
      • 8.1.4.1. Off Patent/Generics Require Reformulating Prior to Use in Needle-Free Delivery Systems
    • 8.1.5. Opportunities
      • 8.1.5.1. Emerging Economies
      • 8.1.5.2. Mass Immunisation Programmes
      • 8.1.5.3. Shift Towards Home Administration Setting
      • 8.1.5.4. Potential Delivery of Vaccines
      • 8.1.5.5. Increasing Global Diabetes Population
      • 8.1.5.6. Extending Life Cycle of Drugs
    • 8.1.6. Threats
      • 8.1.6.1. Traditional Needles and Syringes are Cheap to Mass Produce
      • 8.1.6.2. Limited Clinical Data
      • 8.1.6.3. Increased Scrutiny from Regulatory Bodies
      • 8.1.6.4. Needle and Syringes with Anti Needlestick Injury Technology
  • 8.2. STEP Analysis of the Global Needle-Free Injection Device Market, 2016-2026
    • 8.2.1. Social Factors
    • 8.2.2. Technological Developments
    • 8.2.3. Economic Pressures
    • 8.2.4. Political Issues

9. Research Interview

  • 9.1. Mr David Hoey, CEO, Vaxxas
    • 9.1.1. Vaxxas Overview
    • 9.1.2. Introducing the Nanopatch™
    • 9.1.3. Vaxxas' Leading Strategy: Competition & Collaboration
    • 9.1.4. Future Directions for Vaxxas and the Industry

10. Conclusions

  • 10.1. The Global Needle-Free Injection Device Market, 2015-2026
  • 10.2. Antares Pharma Dominates the Global Needle-Free Injection Device Market in 2016
  • 10.3. Strong Pipeline Will Drive the Competing Needle-Free Injection Technology Market
  • 10.4. The Future of the Needle-Free Technology Market?
  • 10.5. Biosimilars are a Major Driver of the Needle Free Drug Delivery Market
  • 10.6. Concluding Remarks

List of Tables

  • Table 2.1: Examples of Needle-Free Vaccine Delivery Systems, 2016
  • Table 2.2: Examples of Needle-Free Insulin Delivery Systems, 2016
  • Table 2.3: Advantages and Disadvantages of Needle-Free Injection, 2016
  • Table 3.1: The Global Needle-Free Injection Device Market: Revenue Forecast ($bn, AGR %, CAGR %) by Technology, 2015-2020
  • Table 3.2: The Global Needle-Free Injection Device Market: Revenue Forecast ($bn, AGR %, CAGR %) by Technology, 2021-2026
  • Table 3.3: Patent Status of the Seven Top Biologic Drugs, 2015-2029
  • Table 3.4: Classification of Jet Injector Devices, 2016
  • Table 3.5: Vaccine Inhalers in Development, 2016
  • Table 4.1: Antares Pharma: Company Overview, 2016
  • Table 4.2: Antares Pharma: Revenue ($m), AGR (%), CAGR (%), 2010-2015
  • Table 4.3: Antares Pharma Needle-Free Products and Licensing Partnerships, 2016
  • Table 4.4: Antares Pharma Needle-Free Products Pipeline, 2016
  • Table 4.5: Mylan Inc.: Company Overview, 2016
  • Table 4.6: Mylan: EpiPen Revenue ($bn), AGR (%), CAGR (%), 2013-2015
  • Table 4.7: Mylan Inc.: Needle-Free Products, 2016
  • Table 4.8: Bioject Medical Technologies: Company Overview, 2016
  • Table 4.9: Bioject Medical Technologies: Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 4.10: Bioject Needle-Free Products Portfolio, 2016
  • Table 4.11: Bioject Needle-Free Products Pipeline, 2016
  • Table 4.12: Activa Company Overview, 2016
  • Table 4.13: Activa Needle-Free Products Portfolio, 2016
  • Table 4.14: D'Antonio Consultants International Company Overview, 2016
  • Table 4.15: D'Antonio Consultants Needle-Free Products, 2016
  • Table 4.16: D'Antonio Consultants International Needle-Free Pipeline, 2016
  • Table 4.17: National Medical Products: Company Overview, 2016
  • Table 4.18: National Medical Products: Needle-Free Products, 2016
  • Table 4.19: Medical International Technologies: Company Overview, 2016
  • Table 4.20: Medical International Technologies: Needle-Free Products, 2016
  • Table 4.21: PenJet Corporation: Company Overview, 2016
  • Table 4.22: PenJet Corporation: Needle-Free Products, 2016
  • Table 4.23: PharmaJet Corporation: Company Overview, 2016
  • Table 4.24: PharmaJet Corporation: Needle-Free Products, 2016
  • Table 4.25: Valeritas: Company Overview, 2016
  • Table 4.26: Valeritas: Needle-Free Products, 2016
  • Table 4.27: 3M: Company Overview, 2016
  • Table 4.28: 3M: Needle-Free Products, 2016
  • Table 4.29: Zogenix: Company Overview, 2016
  • Table 4.30: Zogenix: Needle-Free Technology 2016
  • Table 4.31: Zogenix: Pipeline, 2016
  • Table 4.32: BD: Company Overview, 2016
  • Table 4.33: BD: Needle-Free Drug Delivery Product Portfolio, 2016
  • Table 4.34: Portal Instruments: Company Overview, 2016
  • Table 4.35: Portal Instruments: Needle-Free Drug Delivery Product Portfolio, 2016
  • Table 5.1: Akra Dermojet: Company Overview, 2016
  • Table 5.2: Akra Dermojet: Needle-Free Technology Portfolio, 2016
  • Table 5.3: Crossject Medical Technology: Company Overview, 2016
  • Table 5.4: Glide Pharma: Company Overview, 2016
  • Table 5.5: Glide Pharma: Needle-Free Products, 2016
  • Table 5.6: Merck KGaA: Company Overview, 2016
  • Table 5.7: Merck KGaA: Needle-Free Injectors, 2016
  • Table 5.8: Spirit Healthcare: Company Overview, 2016
  • Table 5.9: Spirit Healthcare: Needle-Free Injector, 2016
  • Table 5.10: AstraZeneca: Company Overview, 2016
  • Table 5.11: AstraZeneca: Needle-Free Injectors, 2016
  • Table 6.1: Injex Pharma: Company Overview, 2016
  • Table 6.2: Injex Pharma: Needle-Free Products, 2016
  • Table 6.3: Romsons Scientific & Surgical: Company Overview, 2016
  • Table 6.4: Romsons Scientific & Surgical Needle-Free Products, 2016
  • Table 6.5: Binny's Health Care: Company Overview, 2016
  • Table 6.6: Binny's Health Care: Needle-Free Products, 2016
  • Table 7.1: Mika Medical Co.: Company Overview, 2016
  • Table 7.2: Mika Medical Co: Needle-Free Products, 2016
  • Table 7.3: JMS Singapore: Company Overview, 2016
  • Table 7.4: JMS Singapore: Needle-Free Products, 2016
  • Table 7.5: B. Braun Singapore: Company Overview, 2016
  • Table 7.6: B. Braun Singapore: Needle-Free Products, 2016
  • Table 7.7: NanoPass Technology: Company Overview, 2016
  • Table 7.8: NanoPass Technology: Needle-Free Products, 2016
  • Table 7.9: Vaxxas: Company Overview, 2016
  • Table 7.10: Vaxxas: Needle-Free Products, 2016
  • Table 8.1: SWOT Analysis of the Global Needle-Free Injection Device Market, 2016-2026
  • Table 8.2: Average Price for Needle-Free Drug/Vaccine Delivery Technology, 2016
  • Table 8.3: STEP Analysis of the Global Needle-Free Injection Device Market, 2016-2026
  • Table 10.1: The Global Needle-Free Injection Device Market: Revenue Forecast ($bn, AGR %, CAGR %), 2015, 2018, 2020, 2023 and 2026

List of Figures

  • Figure 1.1: Needle-Free Injection Device Market Segmentation, 2016
  • Figure 3.1: The Global Needle-Free Injection Device Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.2: The Global Needle-Free Injection Device Market: Drivers, 2016-2026
  • Figure 3.3: The Global Needle-Free Injection Device Market: Restraints, 2016-2026
  • Figure 4.1: Antares Pharma: Revenue ($m), AGR (%), 2010-2015
  • Figure 4.2: Mylan: EpiPen Revenue ($bn), AGR (%), 2013-2015
  • Figure 4.3: Bioject Medical Technologies: Revenue ($m), AGR (%), 2013-2015
  • Figure 5.1: Crossject Medical Technology: Drugs in Pipeline to Be Exclusively Used With Zeneo, 2016
  • Figure 8.1: The Transport Process for a Vaccine

Companies Listed

  • 3M
  • Actavis
  • Activa Brand Products
  • Aerogen
  • Akra Dermojet
  • ALZA Pharmaceuticals
  • Ankara University
  • Antares Pharma
  • Aradigm Corporation
  • Astellas Pharma
  • AstraZeneca
  • B. Braun Singapore
  • Battelle
  • Becton, Dickinson and Company
  • Bill and Melinda Gates Foundation
  • Binny's Health Care
  • Bioject Medical Technologies
  • BioValve Technologies
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • CDC Measles Eradication Committee
  • Centre for Devices and Radiological Health (CDRH)
  • Centre for Disease Control and Prevention (CDC)
  • China State Food and Drug Administration (SFDA)
  • Covidien
  • Crossject Medical Technology
  • CSL Behring
  • CSL Limited
  • Daewoong Pharmaceuticals
  • Dance Pharmaceuticals
  • D'Antonio Consultants International
  • Diabetes Management International
  • Dr. Reddy's Laboratories
  • Durect Corporation
  • Echo Therapeutics
  • Eli Lilly
  • Eurojet Medical
  • European Union
  • Ferndale Pharma Group
  • Ferring Pharmaceuticals
  • Food and Drug Administration (FDA)
  • Georgia Tech University
  • GlaxoSmithKline (GSK)
  • Glide Pharma
  • Harvard University
  • Injex Pharma AG
  • JCR Pharmaceuticals
  • Jiangsu Hualan Medical International Technologies
  • JMS Singapore
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • MannKind
  • Massachusetts Institute of Technology (MIT)
  • Meda Pharmaceuticals
  • Medical International Technologies
  • MedImmune
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • MGlas AG
  • Mika Medical Co.
  • Minnesota Rubber and Plastics (MRP)
  • MPI Research
  • Mylan
  • NanoPass Technology
  • National Medical Products
  • Nektar Therapeutics
  • North Carolina University
  • Novartis
  • Novo Nordisk
  • Nypro Limited
  • Patheon
  • Penjet Corporation
  • Pfenex Inc.
  • Pfizer
  • PharmaJet
  • Philips Medical
  • Portal Instruments
  • Romsons Scientific & Surgical
  • Sanofi-Aventis
  • Sanofi-Pasteur
  • Spirit Healthcare
  • Takeda
  • Team Consulting
  • Teva Pharmaceuticals
  • UCB
  • University of Colorado
  • US Army Medical Research Institute of Infectious Disease (USAMRIID)
  • Valeritas
  • Vaxxas
  • Weston Medical
  • World Health Organization (WHO)
  • Zogenix
  • Zomajet
  • Zosano Pharma
Back to Top